Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
News
Trending News
All News
Biotech
Buybacks
Commodities
Consumer
Cryptocurrency
Debt/Share Issuance
Dividends - Funds
Dividends - Stocks
Earnings
Energy
Financials
Global Macro
Graphical News
Guidance
Healthcare
IPOs
M&A
Market Pulse
MLPs
Notable Calls
On The Move
Politics
REITs
SPACs
Tech
Top News
U.S Economy
Show Full Stories
Earnings week ahead: Amazon, Apple, Pfizer, AMD, Coca-Cola, Starbucks and more
Amgen’s Blincyto data send Cullinan higher
WHO picks JN.1 variant for next set of COVID vaccines
Aquestive wins FDA approval for anti-seizure therapy Libervant
Cannabis retailer MedMen files for bankruptcy
BrightSpring Health Services appoints Timothy Wick to its board of directors
Achieve Life Sciences files to sell 13.09M shares of common stock for holders
Outlook Therapeutics files to sell 2.78M shares of common stock for holders
Cytokinetics names Sung Lee as CFO
Repare Therapeutics appoints Steven Stein to its board of directors
bluebird bio receives non-compliance notice from Nasdaq
Tobacco companies breathe easier as menthol cigarette ban gets reprieve
Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day
Microsoft, Google, X sent private data from Kaiser Permanente - report
Bristol, Sanofi, Takeda gain positive CHMP recommendations
AbbVie stock slides 6% amid concerns about falling Humira sales
19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard
Pfizer gets FDA approval for hemophilia B gene therapy Beqvez
Cannabis MSOs get date for oral arguments in federal marijuana law case
Medtronic gets FDA okay for Inceptiv closed-loop spinal cord stimulator
AbbVie Q1 report beats Street despite plunging Humira sales
AbbVie off 3% despite quarterly beats, 2024 guidance raise
Applied Dna Sciences, OptimizeRx, SCWorx among healthcare movers
Biodexa shares rally 126% on rapamycin licensing deal
AbbVie in charts: Q1 Skyrizi, Rinvoq sales jump, while revenue from Humira continues to fall
1
2
3
4
5
Next